We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Diaceutics Plc | LSE:DXRX | London | Ordinary Share | GB00BJQTGV64 | ORD GBP0.002 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
7.50 | 6.22% | 128.00 | 123.00 | 128.00 | 125.50 | 120.50 | 120.50 | 67,588 | 16:35:07 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Testing Laboratories | 19.5M | 724k | 0.0085 | 147.65 | 106.31M |
Date | Subject | Author | Discuss |
---|---|---|---|
28/6/2024 11:42 | Buyers back here after the slight pullback....... | chrisdgb | |
29/5/2024 21:59 | Smithie they source actionable data from a wide network of labs and inform pharma companies and physicians when there is an opportunity to deploy some of their expensive and specific drugs, I think for example for Non small cell lung cancer, NSCLC the therapy depends on the cellular expression of Epidermal growth factor and/or a number of others, some of which are more prevalent in certain ethnic groups. for breast cancer, ER, PR, Her2 are the common cellular antigens tested for and can be strongly positive, weakly expressed or absent,status of each can change during the course of the disease, new drugs available now for weakly expressing Her2 and ER so much more nuanced than previously, Neuroendocrine tumours depend on Ki1 Lymphomas -treatment depends on a wide variety of cellular markers some demanding eg no immediate treatment others btk therapy and cytogenetics which are deemed favourable or unfavourable, the latter demanding more intensive therapy or bone marrow transplant thyroid, NTRK or RET, calcitonin, renal tumours combinations of Ck7 and others for different types with very variable prognosis and treatment stomach and increasingly other sites, her2 prostate recurrence reappearance of PSA often first indication their main market should be US as the health system there is much less integrated than, for instance, the NHS where cancer patients should be put through hospital formal meetings where all this is discussed, citrullinated antibody positivity might be first indication of rheumatoid etc I think this is what they do, others correct me if I'm mistaken! | c3479z | |
29/5/2024 14:03 | is anyone willing to explain in a short paragraph what this company actually does ?!! something to do with handling data for big pharma companies.....but I have no idea what the co. does with said data....or how that is of any use to anyone ? & why said pharma companies dont handle their data themselves ? | smithie6 | |
29/5/2024 09:33 | Nice to see this still getting some attention...... | chrisdgb | |
21/5/2024 10:57 | YesLooking goodNice quiet board so under the radar but hopefully someone with deep pockets notices it | pmeldrum | |
21/5/2024 08:31 | very bullish, as mentioned before I have always thought a 200p+ takeover offer is inevitable here...... | chrisdgb | |
16/5/2024 08:11 | Interesting announcement this morning....... | chrisdgb | |
04/4/2024 15:46 | Like a coiled spring......... | chrisdgb | |
15/3/2024 07:26 | Actually, not one of those is available on Research Tree which I also use. This is my point, the notes have been made available only to corporate clients and that is down to the broker as opposed to DXRX.That said, I agree with your point, it's a crying shame that they aren't more readily accessible, but ultimately in this case with many others it's down to the brokers. | hastings | |
15/3/2024 06:47 | Wisecat2, it is wrong to say you can't look at the research unless you pay.Like many other quoted companies the brokers covering DXRX just don't make the info readily available to private investors.It isn't something I agree with as I believe in a level playing field, but it is unfortunately still quite common. I'm fortunate enough to have seen three of the notes including the most recent initiation from Panmure, all of which make for good reading. | hastings | |
15/3/2024 06:38 | Martin follows Filtronic. Have a look at the quality website and then look at DXRX and how cheap and out of date it is. Not good. Look at research no you cant unless you pay not a great way to attract new shareholders. Saying that it is an interesting company but needs to help potential investors, there a lot of cheap quality companies out there | wisecat2 | |
14/3/2024 12:55 | Write up for interest, after catching up with the CEO last week. | hastings | |
14/2/2024 13:11 | Interesting RNS....... | chrisdgb | |
02/2/2024 14:56 | CFO here looks an interesting young chap. Nick Roberts. Left CERES to join Ergomed as number 2 to CFO just before they surged in late 2019/early 2020. Not sure when he left ERGO but has had the leg up to CFO in a smaller business. Hope his track record of picking successful companies continues here. | sevenccc | |
30/1/2024 07:54 | All looking good, on track for my 200p+ takeout eventually...... | chrisdgb | |
19/1/2024 08:28 | Trading update in just over a week.......... | chrisdgb | |
18/12/2023 09:42 | As usual very little activity here but hoping for good things in 24'.... | chrisdgb | |
17/11/2023 08:15 | shares seem well bid at the moment....... | chrisdgb | |
26/9/2023 14:28 | loads of potential: can it turn a decent profit? | 1c3479z | |
26/9/2023 11:57 | 'accelerate the corporate development'........ | chrisdgb | |
30/8/2023 11:31 | Nice to see more interest here.... | chrisdgb | |
25/8/2023 08:24 | Thanks Martin........... | chrisdgb | |
25/8/2023 08:20 | Recently caught up with management, write up for interest. | hastings | |
04/8/2023 09:25 | Nice to see they are spreading the word, US crucial....... | chrisdgb | |
28/7/2023 21:35 | good rise today management and Directors very well remunerated and other benefits, altogether getting more than the annual profit presently although they would argue the company is early in its growth trajectory.... | 1c3479z |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions